RxDoctor Payments Data

Sean McMillan, MD

Rheumatology · Twin Falls, IDNPI 1558353821

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,696 of the $3,866 with a category attached, or 69.7%. Liberty Surgical Inc. accounts for 75.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $2,292 and has fallen 74.0% since, to $595 in 2025.

$3,866in general payments, 2019–2025

Across 24 payments — averaging $161.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Liberty Surgical Inc.$3K
  • Intuitive Surgical$218
  • Amgen$178
  • AbbVie$155
  • Eclipse Technology Solutions Inc.$142
  • Bard Access Systems, Inc.$100
  • plus $144 from 5 others

What the payments were for

  • Travel & lodging$2,69670%
  • Food & beverage$1,16930%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Liberty Surgical Inc.6$2,928
Intuitive Surgical3$218
Amgen4$178
AbbVie4$155
Eclipse Technology Solutions Inc.1$142
Bard Access Systems, Inc.1$100
Bristol Myers Squibb1$43
UCB, Inc.1$43
Boston Scientific1$24
Johnson & Johnson1$19
Sandoz1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,866 in reported general payments places this provider in the 70th percentile of 28 rheumatology providers in Idaho.

See all rheumatology providers in Idaho

Medicare billing

Part B allowed, 2024
$51,378
Medicare patients
219
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept49$375,144
Humira(Cf) PenAdalimumab39$304,206
Xeljanz XrTofacitinib Citrate43$240,270
Humira PenAdalimumab28$183,660
HumiraAdalimumab13$154,249
XeljanzTofacitinib Citrate18$95,051
RinvoqUpadacitinib13$84,033
Cosentyx SyringeSecukinumab13$83,167
OrenciaAbatacept13$74,418
Actemra ActpenTocilizumab29$70,706
Hydroxychloroquine Sulfate570$25,754
Leflunomide206$12,546
Mycophenolate Mofetil60$11,729
MethotrexateMethotrexate Sodium265$6,733
Pilocarpine Hcl23$2,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Rinvoq$155$238,28226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 rheumatology providers in Idaho.

Other rheumatology in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →